ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings

Benzinga Earnings

Aug 07

ICU Medical Inc (NASDAQ:ICUI) on Thursday posted upbeat earnings for the second quarter.

The company reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $1.91 per share. The company reported quarterly sales of $551.700 million which beat the analyst consensus estimate of $533.428 million.

ICU Medical raised its FY2026 adjusted EPS guidance from $7.75-$8.45 to $8.60-$9.00.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.”

ICU Medical shares rose 4.8% to $174.28 in pre-market trading.

These analysts made changes to their price targets on ICU Medical following earnings announcement.

Needham analyst Mike Matson maintained the stock with a Buy and raised the price target from $165 to $187.
BTIG analyst Sam Eiber maintained the stock with a Buy and raised the price target from $170 to $200.

Considering buying ICUI stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2657561732"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657561732\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657561732?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 18:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657561732","market":"hk","top_or_hot":-1,"title":"ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings","media":"Benzinga Earnings","content":"<html><body><p><strong>ICU Medical Inc</strong> (NASDAQ:ICUI) on Thursday posted upbeat earnings for the second quarter.</p>\n<p>The company reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $1.91 per share. The company reported quarterly sales of $551.700 million which beat the analyst consensus estimate of $533.428 million.</p>\n<p>ICU Medical raised its FY2026 adjusted EPS guidance from $7.75-$8.45 to $8.60-$9.00.</p>\n<p>Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.”</p>\n<p>ICU Medical shares rose 4.8% to $174.28 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on ICU Medical following earnings announcement.</p>\n<ul>\n<li>Needham analyst Mike Matson maintained the stock with a Buy and raised the price target from $165 to $187.</li>\n<li>BTIG analyst Sam Eiber maintained the stock with a Buy and raised the price target from $170 to $200.</li>\n</ul>\n<p><strong>Considering buying ICUI stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"321\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/07064034/image-189-1024x321.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/07064034/image-189-1024x321.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/07064034/image-189-300x94.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/07064034/image-189-768x241.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/07064034/image-189.png 1153w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-08-07 18:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>ICU Medical Inc</strong> (NASDAQ:ICUI) on Thursday posted upbeat earnings for the second quarter.</p>\n<p>The company reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $1.91 per share. The company reported quarterly sales of $551.700 million which beat the analyst consensus estimate of $533.428 million.</p>\n<p>ICU Medical raised its FY2026 adjusted EPS guidance from $7.75-$8.45 to $8.60-$9.00.</p>\n<p>Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.”</p>\n<p>ICU Medical shares rose 4.8% to $174.28 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on ICU Medical following earnings announcement.</p>\n<ul>\n<li>Needham analyst Mike Matson maintained the stock with a Buy and raised the price target from $165 to $187.</li>\n<li>BTIG analyst Sam Eiber maintained the stock with a Buy and raised the price target from $170 to $200.</li>\n</ul>\n<p><strong>Considering buying ICUI stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"321\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/07064034/image-189-1024x321.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/07064034/image-189-1024x321.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/07064034/image-189-300x94.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/07064034/image-189-768x241.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/07064034/image-189.png 1153w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICUI","symbol_name":"ICU医疗","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61032699/icu-medical-analysts-boost-their-forecasts-following-upbeat-q2-earnings","article_id":"2657561732","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657561732","pubTimestamp":1786099412,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"\nICU Medical Inc (NASDAQ:ICUI) reported strong Q2 earnings of $2.37 per share and raised its FY2026 guidance. Analysts have increased price targets for the stock.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ICUI":"ICU医疗","ICU":"SeaStar Medical Holding Corporation"},"translate_title":"第二季度盈利乐观后，ICU Medical 分析师上调了预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICU":1.5,"ICUI":1.5},"content_text":"ICU Medical Inc (NASDAQ:ICUI) on Thursday posted upbeat earnings for the second quarter.\nThe company reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $1.91 per share. The company reported quarterly sales of $551.700 million which beat the analyst consensus estimate of $533.428 million.\nICU Medical raised its FY2026 adjusted EPS guidance from $7.75-$8.45 to $8.60-$9.00.\nVivek Jain, ICU Medical’s Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.”\nICU Medical shares rose 4.8% to $174.28 in pre-market trading.\nThese analysts made changes to their price targets on ICU Medical following earnings announcement.\n\nNeedham analyst Mike Matson maintained the stock with a Buy and raised the price target from $165 to $187.\nBTIG analyst Sam Eiber maintained the stock with a Buy and raised the price target from $170 to $200.\n\nConsidering buying ICUI stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}